Gene therapy—delivering a gene into specific cell types so that its expression can treat or cure a disease—is a concept that dates back more than three decades. The field has shown tremendous potential and has now produced approved products that have helped many patients. However, the development of new gene therapies has been beset by safety issues, technical obstacles, and manufacturing cost challenges that have so far restricted their use to a small subset of diseases. It is increasingly accepted that the limitations of current gene therapy approaches are often related to the use of adeno-associated viral vectors (AAVs) or other viral vectors to deliver the genetic material.
Intergalactic Therapeutics was founded by ATP (Apple Tree Partners), a leading life sciences venture capital firm, to overcome the limitations of viral-based gene therapy and develop a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to provide a potentially safer and more effective solution for patients.
Our approach promises benefits beyond patient safety. The integrated Intergalactic platform offers the versatility to treat a broad range of diseases, with simple, fast, and cost-efficient production.
Our Science
Chief Executive Officer
Dr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She most recently served as President and Chief Medical Officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy and supporting the company’s Series C financing. Prior to joining Kriya, Dr. Heah served as Executive Vice President of Operations and Chief Medical Officer at AsclepiX Therapeutics, where she led the company’s Series A financing and advancement of its pipeline products into the clinic. Dr. Heah also previously served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (Fovea Pharmaceuticals) and publicly traded companies (Aerie Pharmaceuticals, Allergan, Bayer Healthcare, Sanofi). Dr. Heah earned her M.D. from Guy’s, King’s and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.
Chief Scientific Officer
José Lora serves as Chief Scientific Officer at Intergalactic Therapeutics, where he brings 20 years’ experience in Research and Development to lead the company’s scientific strategy and operations. Most recently, José was Chief Scientific Officer at enGene, a clinical-stage non-viral gene therapy company focused on gene delivery to mucosal surfaces. At enGene, he and his team were responsible for the conception, development and advancement of EG-70, a plasmid-based therapeutic for the treatment of bladder cancer, to Ph1/Ph2 clinical trials. Prior to enGene, José was Vice President, Research, at Synlogic, a clinical-stage biopharmaceutical company dedicated to the application of synthetic biology to the discovery and development of therapies for metabolic and immune-mediated diseases, and cancer. At Synlogic, José built and led the Immunomodulation therapy area and led a multidisciplinary team to conceive, develop, and advance SYNB1891, an engineered bacterial cell therapy designed to engage the STING pathway in solid tumors, to clinical trials. Prior to Synlogic, he served in several biotech and pharmaceutical companies, including Constellation, GlaxoSmithKline, Roche, and Millennium, in positions of increasing impact and responsibility. José received his Ph.D. from the University of Seville, Spain, and was a postdoctoral researcher at Brown University and the University of Utah. He is co-author of numerous publications, including papers in the Journal of Experimental Medicine, PNAS, Nature, Nature Immunology, Nature Communications, and Nature Reviews.
Chief Technology Officer
Bob Farra is Intergalactic’s Chief Technology Officer. Bob is a hands-on entrepreneur/engineer with expertise in technology and product development of medical devices and combination products including wirelessly enabled wearables, implants, life support systems, drug delivery devices, and surgical and interventional devices. His experience spans all aspects of transforming technologies into successful, commercial products, including research, product development, IP development, regulatory, quality, and manufacturing. Prior to Intergalactic, Bob worked at CeQur Corp, a company focused on reducing the burden of diabetes by eliminating insulin injections. As CEO, he led the development of the company’s proprietary three-day wearable patch for on-demand mealtime insulin as well as the acquisition of the company’s commercial three-day wearable patch. Prior to CeQur, he worked at Microchips, an MIT startup developing implantable drug delivery devices and sensors; there he led the company through the world’s first clinical trial of a wirelessly enabled drug deliver implant. At Microchips, Bob held roles including President and Chief Operating Officer, Chief Technology Officer, and Vice President of R&D. Bob was also Vice President of Engineering and Manufacturing for Abiomed, leading all new product development and commercial manufacturing of ventricular assist devices and the artificial heart program. He also held senior leadership positions at Accellent (now part of Integer), a CMO for medical devices, and Arthur D. Little, a global consulting firm specializing in contract R&D. Bob is currently an active advisor and mentor at MIT and Northeastern University; he was also a former advisor at MGH’s technology assessment and development group and Boston Biomedical Innovation Center, a life science accelerator program funded by the National Institutes of Health. He has over 20 patents and received his Masters of Science in Mechanical Engineering from MIT.
Vice President, Finance Operations
Charles Allen is Vice President of Finance Operations at Intergalactic. He has over 14 years of experience in finance and accounting roles within life science companies ranging from pre-commercial to global top 10 pharma. Before joining Intergalactic, Charles was Senior Director, Finance and Controller of Goldfinch Bio, a clinical stage biotech. He held several finance roles at Takeda Pharmaceuticals, including Global Value Capture Lead in support of Takeda’s acquisition of Shire and Finance Head for the Global Oncology development portfolio. Charles has also held positions at ARIAD Pharmaceuticals (acquired by Takeda), EMD Serono, and Vertex Pharmaceuticals. He earned a B.S. in Business Administration with a concentration in Accounting from the University of Maine and is a certified public accountant in the State of Maryland.
Senior Director, Head of Human Resources
Kim McGonagle is Senior Director and Head of Human Resources at Intergalactic. Kim has over 15 years of experience in Human Resources spanning different industries and company stages. Prior to Intergalactic, she was Director of People & Culture at Life Biosciences, where she led HR for the early-stage biotech. Prior to Life Biosciences, she held various HR leadership roles at Harvest Power, Inc. (acquired by True North Venture Partners) and ABM Industries, Inc. Kim received her B.S. in Business and Economics from the State University of New York at Oneonta and maintains active Professional in Human Resources (PHR) and Society for Human Resources Certified Professional (SHRM-CP) certifications.
Senior Director, Head of Process Development
Meisam is Head of Process Development at Intergalactic Therapeutics, leading design, development, optimization, and tech transfer of C3DNA Drug Substance and Drug Product manufacturing processes to enable the Intergalactic pipeline. Meisam has extensive experience in process development and manufacturing across therapeutic modalities, including protein biologics, AAV viral vectors, plasmid DNA, and lipid nanoparticles. He was most recently Director, Process Development at Tessera Therapeutics, where he led the process development and manufacturing activities for AAV, plasmid DNA, and lipid nanoparticles. Prior to Tessera, he spent 10 years at Biogen in process development roles of increasing scope and responsibilities, including Head of Downstream Process Development for gene therapy and CMC Technical Development Lead for early- and late-stage gene therapy programs. Meisam holds a Ph.D. in Chemical Engineering from Penn State and a M.S and B.S. in Chemical Engineering from Sharif University of Technology in Iran.
Senior Director, Head of Molecular Biology
As Head of Molecular Biology at Intergalactic Therapeutics, Raj leads the C3DNA vector engineering research focused on developing safe and durable non-viral gene delivery vehicles. Raj brings a wealth of industry experience in mRNA therapeutics, non-viral DNA gene therapy, and genome editing, gained over a decade of work at leading companies in this space – Prime Medicine, Generation Bio and Moderna. Before joining Intergalactic, Raj led the Liver Therapeutics group at Prime Medicine, responsible for the preclinical discovery and early development of non-viral prime editing therapies for rare liver diseases. At Generation Bio, Raj headed Cell Biology and Exploratory Biology functions as part of the non-viral DNA gene therapy platform and made significant contributions to optimize the platform technology and expand the reach of the technology to extrahepatic tissues. Before Generation Bio, Raj was the biology lead for multiple liver disease indications at Moderna and has successfully advanced LNP-delivered mRNA medicines through the preclinical development. Raj also worked as Scientist at Broad Institute of Harvard and MIT performing high-throughput small molecule screening and assay development for various genetic targets. Raj obtained his Ph.D. in Virology from the University of Kentucky and completed his postdoctoral training at Dana-Farber Cancer Institute, Harvard Medical School.
Board Chair
Michael Ehlers was the founding CEO of Intergalactic Therapeutics and now serves as the company’s Board Chair. He is also chief scientific officer of, and a venture partner at, ATP (Apple Tree Partners). Mike brings to Intergalactic extensive expertise gained leading research and development at major biopharmaceutical companies. As executive vice president for research and development at Biogen, he led discovery sciences, translational medicine, clinical development and regulatory sciences, with a focus on neurological, immunological and rare diseases. He significantly expanded and diversified Biogen’s clinical portfolio, transformed its research and development productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza™️ (nusinersin), the first drug approved for spinal muscular atrophy. Prior to Biogen, Mike was biotherapeutics group senior vice president and neuroscience chief scientific officer at Pfizer, where he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic. Before entering industry in 2010, Mike was a professor and investigator at the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. He has authored more than 100 scientific papers and served on multiple editorial boards as well as advisory boards for the National Institutes of Health, private foundations and other organizations spanning industry, academia and government. He received a B.S. in Chemistry from the California Institute of Technology and holds an M.D. and Ph.D. from the Johns Hopkins University School of Medicine.
Anna Batarina is a partner at ATP (Apple Tree Partners) and a leader in international business, capital markets, corporate finance and strategy. Anna joined ATP in 2016 from Braeburn, an ATP portfolio company, where she served as vice president of strategic development. Before Braeburn, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that, Anna was senior vice president and head of capital markets and investor relations at Uralkali, a leading global agrochemical business, where she led one of the most successful IPOs on the London Stock Exchange. Anna received an M.A. in Global Affairs (Global Health track) and a graduate certificate in Global Health, Public Health from Yale University. She holds an M.S. in Clinical Psychology from Lomonosov Moscow State University, a B.S. in Finance from Financial University under the Government of the Russian Federation, and a CFA charter.
Seth Harrison is founder and managing partner at ATP (Apple Tree Partners). He began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision and ViroPharma. He currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as all of the portfolio companies created within ATP V, ATP’s current fund, to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention. Seth received an A.B. from Princeton University and holds an M.D. and MBA from Columbia University. He completed a surgery internship at the Presbyterian Hospital in the City of New York.
Dr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She most recently served as President and Chief Medical Officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy and supporting the company’s Series C financing. Prior to joining Kriya, Dr. Heah served as Executive Vice President of Operations and Chief Medical Officer at AsclepiX Therapeutics, where she led the company’s Series A financing and advancement of its pipeline products into the clinic. Dr. Heah also previously served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (Fovea Pharmaceuticals) and publicly traded companies (Aerie Pharmaceuticals, Allergan, Bayer Healthcare, Sanofi). Dr. Heah earned her M.D. from Guy’s, King’s and St. Thomas’ School of Medicine, King’s College, University of London, and her Executive Master’s in Business Administration from the European School of Management & Technology (ESMT), Berlin.
Sangeeta N. Bhatia M.D., Ph.D., is a Professor of Engineering at Massachusetts Institute of Technology (MIT), Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research, and an Investigator of the Howard Hughes Medical Institute. Her laboratory leverages miniaturization tools from the computer industry for medical innovation with applications in liver disease, cancer and infectious diseases. In addition, Sangeeta has contributed to more than 50 issued or pending patents, launched multiple biotechnology companies to improve human health, and published more than 200 peer-reviewed papers. She was the 25th person in history to be an elected member of all three US National Academies: National Academy of Science (NAS), National Academy of Medicine (NAM), and National Academy of Engineering (NAE). She has been honored with the Lemelson-MIT Prize, the Heinz Medal, and the Othmer Gold Medal for groundbreaking inventions and advocacy for women in STEM fields.
Thaddeus Dryja, M.D., is a Professor of Ophthalmology at Harvard Medical School and an eye pathologist at Massachusetts Eye and Ear. At the Novartis Institutes for Biomedical Research, he was the Head of Translational Medicine in Ophthalmology and then the Vice President and Head of Ophthalmology research. His research discoveries included finding compelling evidence for the recessive nature of oncogenic mutations at tumor suppressor genes like the retinoblastoma gene, the identification and cloning of the retinoblastoma gene, and the identification of 16 different genes responsible for retinitis pigmentosa and other forms of retinal degeneration and retinal dysfunction.
Rachel Huckfeldt, M.D., Ph.D., is an Assistant Professor of Ophthalmology at Harvard Medical School and a clinician-scientist in the Inherited Retinal Disorders Service at Massachusetts Eye and Ear (MEE). She completed combined M.D./Ph.D. training at Washington University in St. Louis, followed by an ophthalmology residency at MEE and clinical fellowships in medical retina at the University of Iowa and inherited retinal disorders at MEE. She is the principal investigator for MEE’s participation in multiple first-in-human clinical trials of genetic therapies.
Francisco Quintana, Ph.D., is a Professor of Neurology at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, Harvard Medical School, and an Associate Member at the Broad Institute of Harvard and MIT. He is also the incoming President of the International Society of Neuro Immunology (ISNI). His neuroimmunological research is focused on investigating signaling pathways that control inflammation and neurodegeneration, with the ultimate goal of identifying novel therapeutic targets and biomarkers for immune-mediated and neurodegenerative disorders. Francisco has published over 200 peer reviewed articles and book chapters.
Ulrich von Andrian, M.D., Ph.D., is a Professor of Immunology at Harvard Medical School and a steering committee member of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University. Throughout his career, he has worked to elucidate the multi-faceted fundamental processes that are essential for the body's defense against infections and for the pathogenesis, prevention, and treatment of inflammatory diseases. His work on leukocyte trafficking is now an integral part of every immunology textbook and has helped to lay a conceptual foundation for the development of drugs that block tissue-specific leukocyte trafficking to treat autoimmune diseases.
Weiping Zou, M.D., Ph.D., is a Professor of Pathology, Immunology, Biology and Surgery at the University of Michigan and Director of the Michigan Center of Excellence for Cancer Immunology and Immunotherapy. He was the AACR Cancer Immunology (CIMM) Chairperson 2019-2020 and has served as the AAI Cancer Immunology Abstract Programming Chair for four years. He has published more than 200 articles and book chapters, including 36 articles in Nature, Science, and Cell journal series. His laboratory is one of the most cited research teams in the field of immunology. His early concept of combinatorial immunotherapeutic strategies has laid the foundation for current cancer immunotherapy and has provided rationales for novel combinations.
